IBDEI13J ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19651,0)
 ;;=733.00^^131^1277^43
 ;;^UTILITY(U,$J,358.3,19651,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19651,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,19651,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,19651,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,19652,0)
 ;;=278.00^^131^1277^40
 ;;^UTILITY(U,$J,358.3,19652,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19652,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,19652,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,19652,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,19653,0)
 ;;=278.01^^131^1277^39
 ;;^UTILITY(U,$J,358.3,19653,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19653,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,19653,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,19653,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,19654,0)
 ;;=250.80^^131^1277^10
 ;;^UTILITY(U,$J,358.3,19654,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19654,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,19654,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,19654,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,19655,0)
 ;;=250.00^^131^1277^5
 ;;^UTILITY(U,$J,358.3,19655,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19655,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,19655,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,19655,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,19656,0)
 ;;=250.40^^131^1277^6
 ;;^UTILITY(U,$J,358.3,19656,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19656,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,19656,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,19656,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,19657,0)
 ;;=250.50^^131^1277^9
 ;;^UTILITY(U,$J,358.3,19657,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19657,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,19657,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,19657,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,19658,0)
 ;;=250.60^^131^1277^7
 ;;^UTILITY(U,$J,358.3,19658,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19658,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,19658,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,19658,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,19659,0)
 ;;=250.70^^131^1277^8
 ;;^UTILITY(U,$J,358.3,19659,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19659,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,19659,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,19659,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,19660,0)
 ;;=250.01^^131^1277^4
 ;;^UTILITY(U,$J,358.3,19660,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19660,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,19660,1,5,0)
 ;;=5^DM Type I DM W/O Complications
 ;;^UTILITY(U,$J,358.3,19660,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,19661,0)
 ;;=272.0^^131^1277^22
 ;;^UTILITY(U,$J,358.3,19661,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19661,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,19661,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,19661,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,19662,0)
 ;;=272.1^^131^1277^28
 ;;^UTILITY(U,$J,358.3,19662,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19662,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,19662,1,5,0)
 ;;=5^Hypertriglyceridemia, Pure
 ;;^UTILITY(U,$J,358.3,19662,2)
 ;;=Hypertriglyceridemia, Pure^101303
 ;;^UTILITY(U,$J,358.3,19663,0)
 ;;=272.2^^131^1277^24
 ;;^UTILITY(U,$J,358.3,19663,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19663,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,19663,1,5,0)
 ;;=5^Hyperlipidemia, Mixed
 ;;^UTILITY(U,$J,358.3,19663,2)
 ;;=^78424
